PMID- 24018450
OWN - NLM
STAT- MEDLINE
DCOM- 20140429
LR  - 20191112
IS  - 1732-2693 (Electronic)
IS  - 0032-5449 (Linking)
VI  - 67
DP  - 2013 Aug 12
TI  - Heart rate variability after BRL37344, a beta-3 agonist, in experimental bladder 
      outlet obstruction.
PG  - 848-58
AB  - INTRODUCTION: Bladder overactivity symptoms accompany benign prostatic 
      hyperplasia (BPH) syndrome. The autonomic nervous system (ANS) disturbances may 
      be involved in bladder dysfunction. An ameliorating effect on bladder 
      overactivity is being assigned to the currently investigated beta-3 adrenoreceptor 
      agonists. However, little is known about the influence of beta-3 agonists on ANS 
      activity. The aim of our study was to estimate ANS activity using heart rate 
      variability (HRV) in experimental model of bladder outlet obstruction (BOO), 
      reflecting human BPH. MATERIAL/METHODS: 30 female rats, divided into control, 
      non-treated BOO (LLBOO), and beta-3 agonist (BRL37344) BOO treated (LLBOO+beta3 
      agonist) were studied. BOO was evoked by 5-week long partial proximal urethra 
      ligation. Next, 20-minute resting HRV recordings were performed in each of the 
      studied groups following i.p. administration of the vehicle (LLBOO) or BRL37344 
      (LLBOO+beta3 agonist). RESULTS: LLBOO rats were characterized by diminished NN 
      range, SDNN, and rMSSD in time-domain analysis. Similarly, TP and non-normalized 
      spectral HRV parameters were also decreased. Contrary to these findings, 
      normalized spectral parameters were lower (nLF) and higher (nHF). The animals 
      treated with BRL37344 demonstrated no significant differences in time--domain HRV 
      parameters. In spectral analysis, a decrease in LF and HF, together with a fall 
      in TP, was found. Moreover, both nLF and nHF reached almost the same values in 
      control and beta-3 agonist treated rats. DISSCUSSION: Our data indicates that 
      BRL37344 is an agent abolishing the autonomic imbalance in experimental BOO, 
      which may contribute to relieving the symptoms of bladder overactivity in beta-3 
      agonists treated participants.
FAU - Dobrek, Lukasz
AU  - Dobrek L
AD  - Department of Pathophysiology, Jagiellonian University Medical College.
FAU - Baranowska, Agnieszka
AU  - Baranowska A
FAU - Thor, Piotr J
AU  - Thor PJ
LA  - eng
PT  - Journal Article
DEP - 20130812
PL  - Poland
TA  - Postepy Hig Med Dosw (Online)
JT  - Postepy higieny i medycyny doswiadczalnej (Online)
JID - 101206517
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Ethanolamines)
RN  - 5DZZ1926YW (BRL 37344)
SB  - IM
MH  - Adrenergic beta-Agonists/*pharmacology
MH  - Animals
MH  - Autonomic Nervous System/*drug effects
MH  - Disease Models, Animal
MH  - Ethanolamines/*pharmacology
MH  - Female
MH  - Heart Rate/*drug effects
MH  - Male
MH  - Organ Size
MH  - Prostatic Hyperplasia/complications/physiopathology
MH  - Rats
MH  - Rats, Wistar
MH  - Urinary Bladder/pathology
MH  - Urinary Bladder Neck Obstruction/*drug therapy/etiology/physiopathology
MH  - Urinary Bladder, Overactive/*etiology/physiopathology
EDAT- 2013/09/11 06:00
MHDA- 2014/04/30 06:00
CRDT- 2013/09/11 06:00
PHST- 2013/09/11 06:00 [entrez]
PHST- 2013/09/11 06:00 [pubmed]
PHST- 2014/04/30 06:00 [medline]
AID - 1062437 [pii]
AID - 10.5604/17322693.1062437 [doi]
PST - epublish
SO  - Postepy Hig Med Dosw (Online). 2013 Aug 12;67:848-58. doi: 
      10.5604/17322693.1062437.